2019 sickle cell disease guidelines by the American Society of Hematology: Methodology, challenges, and innovations

M. Hassan Murad*, Robert I. Liem, Eddy S. Lang, Elie A. Akl, Joerg J. Meerpohl, Michael R. DeBaun, John F. Tisdale, Amanda M. Brandow, Sophie M. Lanzkron, Stella T. Chou, Starr Webb, Reem A. Mustafa

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

The American Society of Hematology (ASH) convened 5 guideline panels to develop clinical practice recommendations addressing 5 management areas of highest importance to individuals living with sickle cell disease: pain, cerebrovascular complications, pulmonary and kidney complications, transfusion, and hematopoietic stem cell transplant. Panels were multidisciplinary and consisted of patient representatives, content experts, and methodologists. The Mayo Clinic Evidence-Based Practice Center conducted systematic reviews based on a priori selected questions. In this exposition, we describe the process used by ASH, including the GRADE approach (Grades of Recommendations, Assessment, Development and Evaluation) for rating certainty of the evidence and the GRADE Evidence to Decision Framework. We also describe several unique challenges faced by the guideline panels and the specific innovations and solutions used to address them, including a curriculum to train patients to engage in guideline development, dealing with the opioid crisis, and working with indirect and noncomparative evidence.

Original languageEnglish (US)
Pages (from-to)3945-3950
Number of pages6
JournalBlood Advances
Volume3
Issue number23
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of '2019 sickle cell disease guidelines by the American Society of Hematology: Methodology, challenges, and innovations'. Together they form a unique fingerprint.

Cite this